A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants.
Sponsor study identifier
interventional
66
0 countries
N/A
Study Start
July 24, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
October 24, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 4, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 4, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 17, 2025
Actual (reported)July 24, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 1, 2025
Actual (reported)October 24, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
November 4, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Change in body weight using calibrated weighing machine
To assess the efficacy of test treatment by evaluating change in body weight in Kg assessed within each treatment group and across treatment groups
Day 01 (pre-treatment), Day 45 (+2 days), and Day 90 (+2 days)
Change in Anthropometric Parameters using calibrated measuring tape
Day 01 (pre-treatment), Day 45 (+2 days), and Day 90 (+2 days)
Change in total Fat percentage using Bioimpedance Test
Day 01 (pre-treatment), Day 45 (+2 days), and Day 90 (+2 days)
Change in VO2 Max using Treadmill Walking Test
Day 01 (pre-treatment), Day 45 (+2 days), and Day 90 (+2 days)
Change in Apolipoprotein - ApoA, ApoB
Day 01 (pre-treatment), Day 45 (+2 days), and Day 90 (+2 days)
Change in carbohydrate metabolism through Serum Blood Glucose and PPBG
Day 01 (pre-treatment), Day 45 (+2 days), and Day 90 (+2 days)
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends. Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends. Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends. Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends. Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral
Nayan Patel
NovoBliss Research Pvt Ltd
First Submitted
July 17, 2025
First Posted
August 1, 2025
Study Start
July 24, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
October 24, 2025
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 4, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 1, 2025
Record last verified: 2025-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: